Response to hepatitis B virus vaccination in haemodialysis patients with and without hepatitis C infection.
The aim of this study was to determine the efficacy of hepatitis B virus (HBV) vaccination and the response to vaccine in individuals on haemodialysis with and without HCV infection. From April 2000 to September 2003 all haemodialysis patients referred to the haemodialysis department in a Babol hospital received 4 microg vaccine intramuscularly at 0, 1, and 6 months. All were negative for HBV infection markers (HBcAb, HBsAg and HBsAb). Of 62 patients, 53 (85.5%) responded to vaccination and 26 (49.1%) were high responders. All individuals with HCV infection responded to vaccination. Duration of haemodialysis had no effect on response to vaccination.
Sorkhi
H
H
Department of Paediatric Nephrology, Babol Medical University, Babol, Islamic Republic of Iran. hadisorkhi@yahoo.com
Roushan
M R H
MR
Al Hashemi
G H
GH
Dooki
M R E
MR
Bai
S
S
D000328:Adult; D016022:Case-Control Studies; D016009:Chi-Square Distribution; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006509:Hepatitis B / Q000097:blood / Q000150:complications / Q000276:immunology / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000097:blood; D006512:Hepatitis B Core Antigens / Q000097:blood; D006514:Hepatitis B Surface Antigens / Q000097:blood; D017325:Hepatitis B Vaccines / Q000008:administration & dosage / Q000276:immunology; D006526:Hepatitis C / Q000097:blood / Q000150:complications* / Q000276:immunology; D018937:Hepatitis C Antibodies / Q000097:blood; D006801:Humans; D007115:Immunization Schedule; D007492:Iran; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis / Q000009:adverse effects; D014611:Vaccination / Q000379:methods
C075654:Engerix-B; D006510:Hepatitis B Antibodies; D006512:Hepatitis B Core Antigens; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines; D018937:Hepatitis C Antibodies